ClinicalTrials.gg
CompletedNCT05569954Updated Mar 2, 2026Results posted

Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 50 Years of Age or Older (V116-010, STRIDE-10)

A Phase 3 interventional study of V116 and PPSV23 in Pneumococcal Disease, sponsored by Merck Sharp & Dohme LLC. Completed at 55 sites in 11 countries. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-02.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,484
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing Pneumococcal 21-Valent Conjugate Vaccine in Pneumococcal Infections — 1 open to participants now, 2 under way, 2 of them phase 3. Pneumococcal 21-Valent Conjugate Vaccine · Pneumococcal Infections.

Enrollment
4th of 10
1,484 · median 1,075
Started
2022
with 3 others
Phase 3
9 of 10
1 open now
Registered
5th of 10
by date
Lead sponsor
8 of 10
Merck Sharp & Dohme LLC

Among the 10 studies testing Pneumococcal 21-Valent Conjugate Vaccine in Pneumococcal Infections, this one is the 4th largest by enrollment, is one of 4 that started in 2022, is one of 9 in phase 3, and was the 5th registered.

Pneumococcal Infections

299 studies on the registry are indexed under Pneumococcal Infections; 26 are open to participants now.

Browse Pneumococcal Infections studies →

Open to participants now

1 of the 10 studies testing Pneumococcal 21-Valent Conjugate Vaccine in Pneumococcal Infections is open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About Pneumococcal 21-Valent Conjugate Vaccine

Pneumococcal 21-Valent Conjugate Vaccine: first FDA approval 2024 (CAPVAXIVE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.

This study: 50 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing Pneumococcal 21-Valent Conjugate Vaccine in Pneumococcal Infections, or all of them as a file.
02

Study summary

This is a phase 3, randomized, double-blind, active comparator-controlled study of the safety, tolerability, and immunogenicity of V116 in pneumococcal vaccine-naïve adults 50 years of age and older. The polyvalent (23-valent) pneumococcal vaccine, PPSV23, is the active comparator. In addition to studying safety/tolerability, it is hypothesized that, at 30 days postvaccination, the immunogenicity of V116 is noninferior to PPSV23 for the 12 common serotypes in V116 and PPSV23, and that V116 is superior to PPSV23 for the 9 serotypes unique to V116. It is also hypothesized that V116 is superior to PPSV23 in the percentage of participants with ≥4-fold rise from baseline in unique V116 serotypes, as measured by serotype-specific opsonophagocytic activity (OPA) geometric mean titers (GMTs).

Read the detailed description

Selected participants may be eligible for optional immunogenicity or PBMC substudies extension that will investigate the exploratory objectives.

03

Conditions studied

  • Pneumococcal Disease
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • For females, is not pregnant or breastfeeding and is either not a woman of (WOCBP) or is a WOCBP and uses acceptable /abstinence; and has medical, menstrual, and recent sexual activity history reviewed by the investigator to decrease the chance of inclusion of an early undetected pregnancy

Exclusion criteria

Exclusion Criteria:

  • Has a history of invasive pneumococcal disease (IPD) [positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site] or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1)
  • Has a known to any component of V116 or PPSV23, including diphtheria toxoid
  • Has a known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented (HIV) infection, functional or anatomic asplenia, or history of disease
  • Has a coagulation disorder contraindicating IM vaccination
  • Had a recent febrile illness (defined as oral or tympanic temperature ≥100.4°F [≥38.0°C] or axillary or temporal temperature ≥99.4°F [≥37.4°C]) or received antibiotic therapy for any acute illness occurring \<72 hours before receipt of study vaccine
  • Has a known that is progressing or has required active treatment \<3 years before enrollment
  • Received prior pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside the protocol
  • Received systemic (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed intervention ≥14 days before receipt of study vaccine
  • Is currently receiving therapy, including chemotherapeutic agents or other immunotherapies/immunomodulators used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease
  • Received any nonlive vaccine ≤14 days before receipt of study vaccine or is scheduled to receive any nonlive vaccine ≤30 days after receipt of study vaccine (inactivated influenza and SARS-CoV2 vaccines may be acceptable)
  • Received any ≤30 days before receipt of study vaccine or is scheduled to receive any live virus vaccine ≤30 days after receipt of study vaccine
  • Received a blood transfusion or blood products, including immunoglobulin ≤6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product until the Day 30 postvaccination blood draw is complete
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
1,484 participants (actual)

Study arms

  • Experimental
    V116

    Participants will receive a single intramuscular (IM) vaccination of 0.5 mL of V116 on Day 1.

    Biological: V116

  • Active comparator
    PPSV23

    Participants will receive a single IM vaccination of 0.5 mL of PPSV23 on Day 1.

    Biological: PPSV23

Interventions

  • BiologicalV116

    Sterile 0.5 mL solution in prefilled syringe containing 4 μg of each pneumococcal polysaccharide (PnPs) antigen 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B.

    Also known as: Pneumococcal 21-valent Conjugate Vaccine

  • BiologicalPPSV23

    Drug page: 23-valent pneumococcal capsular polysaccharide vaccine

    Sterile 0.5 mL solution in prefilled syringe containing 25 μg of each PnPs antigen 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F.

    Also known as: PNEUMOVAX™23

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Solicited Injection-Site Adverse Events (AEs)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited injection-site AEs consisted of pain/tenderness, redness/erythema, and swelling. 95% confidence intervals (CIs) for between-group differences are provided using the Miettinen \& Nurminen method.

    Time frame: Up to 5 days postvaccination

  2. Percentage of Participants With Solicited Systemic AEs

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited systemic AEs consist of the following: fatigue (tiredness), headache, myalgia (muscle aches), and pyrexia (maximum temperature ≥ 100.4 °F/38.0 °C). 95% confidence intervals (CIs) for between-group differences are provided using the Miettinen \& Nurminen method.

    Time frame: Up to 5 days postvaccination

  3. Percentage of Participants With Vaccine-Related Serious Adverse Events (SAEs)

    An SAE is any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongs existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an other important medical event. SAEs that were reported to be at least possibly related by the investigator to study vaccination are summarized. 95% confidence intervals (CIs) for between-group differences are provided using the Miettinen \& Nurminen method.

    Time frame: Up to 6 months postvaccination

  4. Serotype-Specific Opsonophagocytic (OPA) Geometric Mean Titers (GMTs) for All Serotypes in V116

    Serotype-specific OPA titers for all serotypes in V116 following vaccination were determined using multiplex opsonophagocytic assay (MOPA). Serotype-specific OPA GMTs and GMT ratios with 95% confidence intervals (CIs), and they hypothesis test (1-sided p-value), were calculated using a constrained longitudinal data analysis (cLDA) model. Per protocol, within-group CIs, or any other method of dispersion were not planned or calculated.

    Time frame: Day 30 postvaccination

  5. Percentage of Participants With ≥4-fold Rise From Baseline in Serotype-Specific OPAs for Serotypes Unique to V116

    The percentage of participants with ≥4-fold rise from baseline in serotype-specific OPAs for the unique pneumococcal serotypes contained in V116 was determined. The 9 unique pneumococcal serotypes in V116 are as follows: 6A, 15A, 15C, 16F, 23A, 23B, 24F, 31, and 35B. Per protocol, within-group CIs, or any other method of dispersion were not planned or calculated.

    Time frame: Baseline (Day 1) and Day 30 postvaccination

Secondary outcomes

  1. Percentage of Participants With ≥4-fold Rise From Baseline in Serotype-Specific Cross-Reactive OPAs

    OPA induced by serotypes 6A and 15C in V116 but cross-reactive to serotypes 6C and 15B, respectively, were measured. The percentage of participants with ≥4-fold rise from baseline in serotype-specific cross-reactive OPAs was determined. Point estimate, 95% CI, and p-value are based on the Clopper-Pearson method. Per protocol, this outcome measure was not planned or analyzed in the PPSV23 study arm.

    Time frame: Baseline (Day 1) and Day 30 postvaccination

  2. Serotype-Specific Geometric Mean Fold Rise (GMFR) of OPA GMTs for All Serotypes in V116

    The GMFR from baseline in serotype-specific OPA GMTs for all serotypes in V116 was determined using MOPA. The within-group 95% CIs are obtained by exponentiating the CIs of the mean of the natural log values based on the t-distribution.

    Time frame: Baseline (Day 1) and Day 30 postvaccination

  3. Serotype-Specific Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for All Serotypes in V116

    The GMCs for serotype-specific IgG antibodies for all serotypes in V116 were determined using pneumococcal electrochemiluminescence (PnECL). The GMC ratio estimation and 95% CI were calculated using a cLDA method. Per protocol, within-group CIs, or any other method of dispersion were not planned or calculated.

    Time frame: Day 30 postvaccination

  4. Serotype-Specific GMFR of IgG GMCs for All Serotypes in V116

    The GMFR from baseline in GMCs for serotype-specific IgG antibodies for all serotypes in V116 was determined using PnECL. The within-group 95% CIs are obtained by exponentiating the CIs of the mean of the natural log values based on the t-distribution.

    Time frame: Baseline (Day 1) and Day 30 postvaccination

  5. Percentage of Participants With ≥4-Fold Rise From Baseline in Serotype-Specific OPA GMTs for All Serotypes in V116

    The percentage of participants with ≥4-fold rise from baseline in serotype-specific OPA GMTs for all serotypes in V116 was determined with MOPA. The within-group CIs were calculated based on the Clopper-Pearson method.

    Time frame: Baseline (Day 1) and Day 30 postvaccination

  6. Percentage of Participants With ≥4-Fold Rise From Baseline in Serotype-Specific IgG GMCs for All Serotypes in V116

    The percentage of participants with ≥4-fold rise from baseline in serotype-specific IgG GMCs for all serotypes in V116 was determined using PnECL. The within-group CIs were calculated based on the Clopper-Pearson method.

    Time frame: Baseline (Day 1) and Day 30 postvaccination

07

Results

Posted Oct 31, 2024

Participant flow

Base Study
Participant flow — Base Study
MilestoneV116PPSV23
Started741743
Vaccinated739741
Completed733735
Not completed88
Withdrew: Lost to follow-up34
Withdrew: Protocol violation12
Withdrew: Withdrawal by subject42
Immunogenicity Substudy Extension
Participant flow — Immunogenicity Substudy Extension
MilestoneV116PPSV23
Started350350
Vaccinated349348
Completed335338
Not completed1512
Withdrew: Lost to follow-up34
Withdrew: Randomized by mistake without study treatment02
Withdrew: Withdrawal by subject125
Withdrew: Non-study pneumococcal vaccine administered01
PBMC Substudy Extension
Participant flow — PBMC Substudy Extension
MilestoneV116PPSV23
Started4139
Vaccinated4139
Completed3939
Not completed20
Withdrew: Withdrawal by subject20

Outcome measures

PrimaryPercentage of Participants With Solicited Injection-Site Adverse Events (AEs)

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited injection-site AEs consisted of pain/tenderness, redness/erythema, and swelling. 95% confidence intervals (CIs) for between-group differences are provided using the Miettinen \& Nurminen method.

Time frame:
Up to 5 days postvaccination
Reported as:
Number · Percentage of Participants
Percentage of Participants With Solicited Injection-Site Adverse Events (AEs)
Percentage of ParticipantsBase Study: V116Base Study: PPSV23
Injection site erythema4.76.3
Injection site pain39.035.2
Injection site swelling4.94.3
Statistical analysis
  • Base Study: V116 vs Base Study: PPSV23 · Difference in percent: -1.6 · 95% CI -4.0 to 0.7V116 minus PPSV23
  • Base Study: V116 vs Base Study: PPSV23 · Difference in percent: 3.7 · 95% CI -1.2 to 8.7V116 minus PPSV23
  • Base Study: V116 vs Base Study: PPSV23 · Difference in percent: 0.6 · 95% CI -1.6 to 2.7V116 minus PPSV23
PrimaryPercentage of Participants With Solicited Systemic AEs

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited systemic AEs consist of the following: fatigue (tiredness), headache, myalgia (muscle aches), and pyrexia (maximum temperature ≥ 100.4 °F/38.0 °C). 95% confidence intervals (CIs) for between-group differences are provided using the Miettinen \& Nurminen method.

Time frame:
Up to 5 days postvaccination
Reported as:
Number · Percentage of Participants
Percentage of Participants With Solicited Systemic AEs
Percentage of ParticipantsBase Study: V116Base Study: PPSV23
Fatigue16.515.7
Headache13.712.0
Myalgia5.35.9
Pyrexia1.11.3
Statistical analysis
  • Base Study: V116 vs Base Study: PPSV23 · Difference in percent: 0.9 · 95% CI -2.9 to 4.6V116 minus PPSV23
  • Base Study: V116 vs Base Study: PPSV23 · Difference in percent: 1.7 · 95% CI -1.8 to 5.1V116 minus PPSV23
  • Base Study: V116 vs Base Study: PPSV23 · Difference in percent: -0.7 · 95% CI -3.1 to 1.7V116 minus PPSV23
  • Base Study: V116 vs Base Study: PPSV23 · Difference in percent: -0.3 · 95% CI -1.5 to 0.9V116 minus PPSV23
PrimaryPercentage of Participants With Vaccine-Related Serious Adverse Events (SAEs)

An SAE is any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongs existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an other important medical event. SAEs that were reported to be at least possibly related by the investigator to study vaccination are summarized. 95% confidence intervals (CIs) for between-group differences are provided using the Miettinen \& Nurminen method.

Time frame:
Up to 6 months postvaccination
Reported as:
Number · Percentage of Participants
Percentage of Participants With Vaccine-Related Serious Adverse Events (SAEs)
Percentage of ParticipantsBase Study: V116Base Study: PPSV23
Percentage of Participants With Vaccine-Related Serious Adverse Events (SAEs)00
Statistical analysis
  • Base Study: V116 vs Base Study: PPSV23 · Difference in percent: 0.0 · 95% CI -0.5 to 0.5V116 minus PPSV23
PrimarySerotype-Specific Opsonophagocytic (OPA) Geometric Mean Titers (GMTs) for All Serotypes in V116

Serotype-specific OPA titers for all serotypes in V116 following vaccination were determined using multiplex opsonophagocytic assay (MOPA). Serotype-specific OPA GMTs and GMT ratios with 95% confidence intervals (CIs), and they hypothesis test (1-sided p-value), were calculated using a constrained longitudinal data analysis (cLDA) model. Per protocol, within-group CIs, or any other method of dispersion were not planned or calculated.

Time frame:
Day 30 postvaccination
Reported as:
Geometric mean · Titers
Serotype-Specific Opsonophagocytic (OPA) Geometric Mean Titers (GMTs) for All Serotypes in V116
TitersBase Study: V116Base Study: PPSV23
3230.4 (NA to NA)211.5 (NA to NA)
7F4876.7 (NA to NA)3314.6 (NA to NA)
83379.6 (NA to NA)2882.1 (NA to NA)
9N7346.6 (NA to NA)6545.9 (NA to NA)
10A4382.9 (NA to NA)2818.7 (NA to NA)
11A3711.1 (NA to NA)1809.7 (NA to NA)
12F3031.8 (NA to NA)1854.9 (NA to NA)
17F8215.7 (NA to NA)4060.5 (NA to NA)
19A2670.0 (NA to NA)1879.9 (NA to NA)
20A6966.1 (NA to NA)4208.4 (NA to NA)
22F4724.1 (NA to NA)3084.9 (NA to NA)
33F15497.3 (NA to NA)17483.0 (NA to NA)
6A3193.9 (NA to NA)964.0 (NA to NA)
15A6746.5 (NA to NA)1462.1 (NA to NA)
15C7604.8 (NA to NA)2605.0 (NA to NA)
16F6675.4 (NA to NA)1482.2 (NA to NA)
23A4804.2 (NA to NA)837.2 (NA to NA)
23B2252.6 (NA to NA)137.2 (NA to NA)
24F4568.0 (NA to NA)1346.7 (NA to NA)
315040.7 (NA to NA)423.9 (NA to NA)
35B10707.5 (NA to NA)1735.0 (NA to NA)
Statistical analysis
  • Base Study: V116 vs Base Study: PPSV23 · cLDA model · p = <0.001 (1-sided) · Gmt ratio: 1.09 · 95% CI 0.96 to 1.23V116/PPSV23
  • Base Study: V116 vs Base Study: PPSV23 · cLDA model · p = <0.001 (1-sided) · Gmt ratio: 1.47 · 95% CI 1.29 to 1.68V116/PPSV23
  • Base Study: V116 vs Base Study: PPSV23 · cLDA model · p = <0.001 (1-sided) · Gmt ratio: 1.17 · 95% CI 1.04 to 1.32V116/PPSV23
  • Base Study: V116 vs Base Study: PPSV23 · cLDA model · p = <0.001 (1-sided) · Gmt ratio: 1.12 · 95% CI 1.00 to 1.26V116/PPSV23
  • Base Study: V116 vs Base Study: PPSV23 · cLDA model · p = <0.001 · Gmt ratio: 1.55 · 95% CI 1.37 to 1.77V116/PPSV23
  • Base Study: V116 vs Base Study: PPSV23 · cLDA model · p = <0.001 · Gmt ratio: 2.05 · 95% CI 1.82 to 2.31V116/PPSV23
  • Base Study: V116 vs Base Study: PPSV23 · cLDA model · p = <0.001 · Gmt ratio: 1.63 · 95% CI 1.40 to 1.90V116/PPSV23
  • Base Study: V116 vs Base Study: PPSV23 · cLDA model · p = <0.001 · Gmt ratio: 2.02 · 95% CI 1.77 to 2.31V116/PPSV23
  • Base Study: V116 vs Base Study: PPSV23 · cLDA model · p = <0.001 · Gmt ratio: 1.42 · 95% CI 1.26 to 1.60V116/PPSV23
  • Base Study: V116 vs Base Study: PPSV23 · cLDA model · p = <0.001 · Gmt ratio: 1.66 · 95% CI 1.46 to 1.88V116/PPSV23
  • Base Study: V116 vs Base Study: PPSV23 · cLDA model · p = <0.001 · Gmt ratio: 1.53 · 95% CI 1.34 to 1.75V116/PPSV23
  • Base Study: V116 vs Base Study: PPSV23 · cLDA model · p = <0.001 · Gmt ratio: 0.89 · 95% CI 0.76 to 1.04V116/PPSV23
  • Base Study: V116 vs Base Study: PPSV23 · cLDA model · p = <0.001 (1-sided) · Gmt ratio: 3.31 · 95% CI 2.84 to 3.87V116/PPSV23
  • Base Study: V116 vs Base Study: PPSV23 · cLDA model · p = <0.001 (1-sided) · Gmt ratio: 4.61 · 95% CI 3.99 to 5.33V116/PPSV23
  • Base Study: V116 vs Base Study: PPSV23 · cLDA model · p = <0.001 (1-sided) · Gmt ratio: 2.92 · 95% CI 2.50 to 3.42V116/PPSV23
  • Base Study: V116 vs Base Study: PPSV23 · cLDA model · p = <0.001 (1-sided) · Gmt ratio: 4.50 · 95% CI 3.99 to 5.09V116/PPSV23
  • Base Study: V116 vs Base Study: PPSV23 · cLDA model · p = <0.001 (1-sided) · Gmt ratio: 5.74 · 95% CI 4.81 to 6.85V116/PPSV23
  • Base Study: V116 vs Base Study: PPSV23 · cLDA model · p = <0.001 (1-sided) · Gmt ratio: 16.42 · 95% CI 13.46 to 20.03V116/PPSV23
  • Base Study: V116 vs Base Study: PPSV23 · cLDA model · p = <0.001 (1-sided) · Gmt ratio: 3.39 · 95% CI 2.97 to 3.87V116/PPSV23
  • Base Study: V116 vs Base Study: PPSV23 · cLDA model · p = <0.001 (1-sided) · Gmt ratio: 11.89 · 95% CI 10.16 to 13.91V116/PPSV23
  • Base Study: V116 vs Base Study: PPSV23 · cLDA model · p = <0.001 (1-sided) · Gmt ratio: 6.17 · 95% CI 5.54 to 6.87V116/PPSV23
PrimaryPercentage of Participants With ≥4-fold Rise From Baseline in Serotype-Specific OPAs for Serotypes Unique to V116

The percentage of participants with ≥4-fold rise from baseline in serotype-specific OPAs for the unique pneumococcal serotypes contained in V116 was determined. The 9 unique pneumococcal serotypes in V116 are as follows: 6A, 15A, 15C, 16F, 23A, 23B, 24F, 31, and 35B. Per protocol, within-group CIs, or any other method of dispersion were not planned or calculated.

Time frame:
Baseline (Day 1) and Day 30 postvaccination
Reported as:
Number · Percentage of Participants
Percentage of Participants With ≥4-fold Rise From Baseline in Serotype-Specific OPAs for Serotypes Unique to V116
Percentage of ParticipantsBase Study: V116Base Study: PPSV23
6A79.1 (NA to NA)53.0 (NA to NA)
15A69.7 (NA to NA)30.3 (NA to NA)
15C87.9 (NA to NA)76.2 (NA to NA)
16F63.2 (NA to NA)20.3 (NA to NA)
23A70.6 (NA to NA)34.7 (NA to NA)
23B86.6 (NA to NA)44.1 (NA to NA)
24F50.5 (NA to NA)14.6 (NA to NA)
3174.4 (NA to NA)18.3 (NA to NA)
35B63.8 (NA to NA)5.2 (NA to NA)
Statistical analysis
  • Base Study: V116 vs Base Study: PPSV23 · Stratified Miettinen & Nurminen method · p = <0.001 (1-sided) · Percent difference: 26.0 · 95% CI 20.9 to 31.0V116 minus PPSV23
  • Base Study: V116 vs Base Study: PPSV23 · Stratified Miettinen & Nurminen method · p = <0.001 (1-sided) · Percent difference: 39.4 · 95% CI 33.6 to 44.8V116 minus PPSV23
  • Base Study: V116 vs Base Study: PPSV23 · Stratified Miettinen & Nurminen method · p = 0.214 (1-sided) · Percent difference: 11.7 · 95% CI 7.5 to 15.9V116 minus PPSV23
  • Base Study: V116 vs Base Study: PPSV23 · Stratified Miettinen & Nurminen method · p = <0.001 (1-sided) · Percent difference: 42.9 · 95% CI 37.8 to 47.8V116 minus PPSV23
  • Base Study: V116 vs Base Study: PPSV23 · Stratified Miettinen & Nurminen method · p = <0.001 (1-sided) · Percent difference: 35.9 · 95% CI 29.6 to 41.8V16 minus PPSV23
  • Base Study: V116 vs Base Study: PPSV23 · Stratified Miettinen & Nurminen method · p = <0.001 (1-sided) · Percent difference: 42.4 · 95% CI 37.6 to 47.0V116 minus PPSV23
  • Base Study: V116 vs Base Study: PPSV23 · Stratified Miettinen & Nurminen method · p = <0.001 (1-sided) · Percent difference: 35.9 · 95% CI 30.6 to 41.0V116 minus PPSV23
  • Base Study: V116 vs Base Study: PPSV23 · Stratified Miettinen & Nurminen method · p = <0.001 (1-sided) · Percent difference: 56.2 · 95% CI 51.5 to 60.5V116 minus PPSV23
  • Base Study: V116 vs Base Study: PPSV23 · Stratified Miettinen & Nurminen method · p = <0.001 (1-sided) · Percent difference: 58.7 · 95% CI 54.6 to 62.7V116 minus PPSV23
SecondaryPercentage of Participants With ≥4-fold Rise From Baseline in Serotype-Specific Cross-Reactive OPAs

OPA induced by serotypes 6A and 15C in V116 but cross-reactive to serotypes 6C and 15B, respectively, were measured. The percentage of participants with ≥4-fold rise from baseline in serotype-specific cross-reactive OPAs was determined. Point estimate, 95% CI, and p-value are based on the Clopper-Pearson method. Per protocol, this outcome measure was not planned or analyzed in the PPSV23 study arm.

Time frame:
Baseline (Day 1) and Day 30 postvaccination
Reported as:
Number · Percentage of Participants
Percentage of Participants With ≥4-fold Rise From Baseline in Serotype-Specific Cross-Reactive OPAs
Percentage of ParticipantsBase Study: V116Base Study: PPSV23
6C52.7 (48.7 to 56.7)—
15B72.6 (68.8 to 76.2)—
Statistical analysis
  • Base Study: V116 · Clopper-Pearson method · p = 0.093 (1-sided)
  • Base Study: V116 · Clopper-Pearson method · p = <0.001 (1-sided)
SecondarySerotype-Specific Geometric Mean Fold Rise (GMFR) of OPA GMTs for All Serotypes in V116

The GMFR from baseline in serotype-specific OPA GMTs for all serotypes in V116 was determined using MOPA. The within-group 95% CIs are obtained by exponentiating the CIs of the mean of the natural log values based on the t-distribution.

Time frame:
Baseline (Day 1) and Day 30 postvaccination
Reported as:
Geometric mean · Ratio
Serotype-Specific Geometric Mean Fold Rise (GMFR) of OPA GMTs for All Serotypes in V116
RatioBase Study: V116Base Study: PPSV23
37.5 (6.8 to 8.3)6.8 (6.2 to 7.5)
7F18.3 (15.8 to 21.1)14.0 (12.2 to 16.1)
834.3 (29.6 to 39.8)28.8 (25.1 to 33.0)
9N11.3 (10.0 to 12.8)11.4 (10.1 to 12.8)
10A16.6 (14.3 to 19.1)10.9 (9.5 to 12.4)
11A18.5 (15.7 to 21.7)9.2 (7.9 to 10.8)
12F89.2 (78.1 to 101.8)58.1 (50.5 to 66.8)
17F25.2 (21.7 to 29.3)12.9 (11.3 to 14.8)
19A10.2 (9.1 to 11.4)7.2 (6.5 to 8.0)
20A10.9 (9.7 to 12.2)6.6 (5.9 to 7.3)
22F20.5 (17.4 to 24.1)12.3 (10.5 to 14.3)
33F8.8 (7.8 to 10.0)10.2 (9.0 to 11.6)
6A19.5 (16.9 to 22.4)5.5 (4.8 to 6.3)
15A10.4 (9.0 to 12.1)2.4 (2.1 to 2.7)
15C49.4 (42.4 to 57.6)17.3 (15.1 to 19.8)
16F7.0 (6.3 to 7.8)1.8 (1.6 to 1.9)
23A13.9 (11.7 to 16.5)2.7 (2.2 to 3.2)
23B53.9 (45.9 to 63.3)4.5 (3.9 to 5.2)
24F5.5 (4.8 to 6.3)1.6 (1.4 to 1.8)
3119.5 (16.7 to 22.8)1.7 (1.5 to 1.9)
35B7.0 (6.3 to 7.8)1.1 (1.1 to 1.2)
SecondarySerotype-Specific Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for All Serotypes in V116

The GMCs for serotype-specific IgG antibodies for all serotypes in V116 were determined using pneumococcal electrochemiluminescence (PnECL). The GMC ratio estimation and 95% CI were calculated using a cLDA method. Per protocol, within-group CIs, or any other method of dispersion were not planned or calculated.

Time frame:
Day 30 postvaccination
Reported as:
Number · μg/mL
Serotype-Specific Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for All Serotypes in V116
μg/mLBase Study: V116Base Study: PPSV23
30.79 (NA to NA)0.69 (NA to NA)
7F9.35 (NA to NA)5.02 (NA to NA)
813.83 (NA to NA)11.85 (NA to NA)
9N11.21 (NA to NA)7.23 (NA to NA)
10A15.05 (NA to NA)7.41 (NA to NA)
11A8.83 (NA to NA)4.01 (NA to NA)
12F2.28 (NA to NA)1.14 (NA to NA)
17F16.39 (NA to NA)6.85 (NA to NA)
19A9.54 (NA to NA)6.42 (NA to NA)
20A22.97 (NA to NA)12.32 (NA to NA)
22F5.32 (NA to NA)3.00 (NA to NA)
33F19.12 (NA to NA)15.70 (NA to NA)
6A5.79 (NA to NA)1.53 (NA to NA)
15A17.98 (NA to NA)2.01 (NA to NA)
15C19.27 (NA to NA)5.61 (NA to NA)
16F3.48 (NA to NA)0.35 (NA to NA)
23A4.21 (NA to NA)0.56 (NA to NA)
23B5.74 (NA to NA)1.20 (NA to NA)
24F8.52 (NA to NA)0.40 (NA to NA)
313.48 (NA to NA)0.40 (NA to NA)
35B22.26 (NA to NA)1.43 (NA to NA)
Statistical analysis
  • Base Study: V116 vs Base Study: PPSV23 · Gmc ratio: 1.14 · 95% CI 1.04 to 1.25V116/PPSV23
  • Base Study: V116 vs Base Study: PPSV23 · Gmc ratio: 1.86 · 95% CI 1.65 to 2.10V116/PPSV23
  • Base Study: V116 vs Base Study: PPSV23 · Gmc ratio: 1.17 · 95% CI 1.04 to 1.31V116/PPSV23
  • Base Study: V116 vs Base Study: PPSV23 · Gmc ratio: 1.55 · 95% CI 1.37 to 1.76V116/PPSV23
  • Base Study: V116 vs Base Study: PPSV23 · Gmc ratio: 2.03 · 95% CI 1.79 to 2.31V116/PPSV23
  • Base Study: V116 vs Base Study: PPSV23 · Gmc ratio: 2.20 · 95% CI 1.97 to 2.46V116/PPSV23
  • Base Study: V116 vs Base Study: PPSV23 · Gmc ratio: 1.99 · 95% CI 1.72 to 2.30V116/PPSV23
  • Base Study: V116 vs Base Study: PPSV23 · Gmc ratio: 2.39 · 95% CI 2.12 to 2.70V116/PPSV23
  • Base Study: V116 vs Base Study: PPSV23 · Gmc ratio: 1.49 · 95% CI 1.32 to 1.67
  • Base Study: V116 vs Base Study: PPSV23 · Gmc ratio: 1.86 · 95% CI 1.65 to 2.10V116/PPSV23
  • Base Study: V116 vs Base Study: PPSV23 · Gmc ratio: 1.77 · 95% CI 1.55 to 2.02V116/PPSV23
  • Base Study: V116 vs Base Study: PPSV23 · Gmc ratio: 1.22 · 95% CI 1.08 to 1.37V116/PPSV23
  • Base Study: V116 vs Base Study: PPSV23 · Gmc ratio: 3.78 · 95% CI 3.29 to 4.35V116/PPSV23
  • Base Study: V116 vs Base Study: PPSV23 · Gmc ratio: 8.92 · 95% CI 7.89 to 10.09V116/PPSV23
  • Base Study: V116 vs Base Study: PPSV23 · Gmc ratio: 3.43 · 95% CI 3.01 to 3.92V116/PPSV23
  • Base Study: V116 vs Base Study: PPSV23 · Gmc ratio: 9.84 · 95% CI 8.83 to 10.97V116/PPSV23
  • Base Study: V116 vs Base Study: PPSV23 · Gmc ratio: 7.59 · 95% CI 6.68 to 8.61V116/PPSV23
  • Base Study: V116 vs Base Study: PPSV23 · Gmc ratio: 4.79 · 95% CI 4.26 to 5.38V116/PPSV23
  • Base Study: V116 vs Base Study: PPSV23 · Gmc ratio: 21.19 · 95% CI 18.98 to 23.65V116/PPSV23
  • Base Study: V116 vs Base Study: PPSV23 · Gmc ratio: 8.69 · 95% CI 7.82 to 9.65V116/PPSV23
  • Base Study: V116 vs Base Study: PPSV23 · Gmc ratio: 15.53 · 95% CI 14.13 to 17.07V116/PPSV23
SecondarySerotype-Specific GMFR of IgG GMCs for All Serotypes in V116

The GMFR from baseline in GMCs for serotype-specific IgG antibodies for all serotypes in V116 was determined using PnECL. The within-group 95% CIs are obtained by exponentiating the CIs of the mean of the natural log values based on the t-distribution.

Time frame:
Baseline (Day 1) and Day 30 postvaccination
Reported as:
Geometric mean · Ratio
Serotype-Specific GMFR of IgG GMCs for All Serotypes in V116
RatioBase Study: V116Base Study: PPSV23
35.3 (5.0 to 5.8)4.7 (4.4 to 5.0)
7F19.3 (17.5 to 21.4)10.9 (10.0 to 11.8)
816.4 (14.9 to 18.1)14.1 (13.0 to 15.3)
9N20.1 (18.1 to 22.4)13.3 (12.2 to 14.5)
10A22.3 (20.2 to 24.7)11.1 (10.2 to 12.1)
11A10.9 (9.8 to 12.0)5.0 (4.7 to 5.4)
12F20.5 (18.4 to 22.9)10.6 (9.5 to 11.7)
17F25.5 (23.1 to 28.1)10.8 (9.9 to 11.8)
19A7.8 (7.1 to 8.6)5.3 (4.9 to 5.7)
20A15.8 (14.4 to 17.3)8.6 (7.9 to 9.3)
22F19.1 (17.3 to 21.2)11.0 (10.0 to 12.1)
33F14.4 (13.1 to 15.8)12.0 (11.0 to 13.0)
6A17.1 (15.3 to 19.0)4.6 (4.2 to 5.1)
15A27.5 (24.9 to 30.4)3.1 (2.9 to 3.4)
15C30.1 (27.1 to 33.4)8.8 (8.0 to 9.6)
16F15.4 (14.1 to 16.9)1.6 (1.5 to 1.7)
23A20.4 (18.4 to 22.6)2.8 (2.6 to 3.0)
23B13.3 (12.0 to 14.7)2.9 (2.7 to 3.1)
24F23.0 (20.8 to 25.6)1.1 (1.1 to 1.1)
3113.0 (11.9 to 14.3)1.6 (1.5 to 1.7)
35B16.8 (15.3 to 18.5)1.1 (1.0 to 1.1)
SecondaryPercentage of Participants With ≥4-Fold Rise From Baseline in Serotype-Specific OPA GMTs for All Serotypes in V116

The percentage of participants with ≥4-fold rise from baseline in serotype-specific OPA GMTs for all serotypes in V116 was determined with MOPA. The within-group CIs were calculated based on the Clopper-Pearson method.

Time frame:
Baseline (Day 1) and Day 30 postvaccination
Reported as:
Number · Percentage of Participants
Percentage of Participants With ≥4-Fold Rise From Baseline in Serotype-Specific OPA GMTs for All Serotypes in V116
Percentage of ParticipantsBase Study: V116Base Study: PPSV23
369.2 (65.4 to 72.9)66.9 (62.9 to 70.7)
7F75.2 (71.7 to 78.5)69.9 (66.2 to 73.4)
883.6 (80.5 to 86.3)85.4 (82.5 to 88.0)
9N72.3 (68.6 to 75.9)73.3 (69.5 to 76.8)
10A74.7 (71.1 to 78.1)66.5 (62.6 to 70.2)
11A72.1 (68.4 to 75.5)58.8 (54.9 to 62.6)
12F93.3 (91.1 to 95.0)90.7 (88.3 to 92.8)
17F84.1 (80.9 to 87.0)71.8 (68.0 to 75.3)
19A70.9 (67.3 to 74.3)64.1 (60.3 to 67.7)
20A71.0 (67.5 to 74.4)58.1 (54.3 to 61.8)
22F76.5 (72.9 to 79.8)67.2 (63.3 to 70.9)
33F66.2 (62.2 to 70.0)70.9 (67.1 to 74.5)
6A79.1 (75.7 to 82.2)53.0 (49.0 to 57.0)
15A69.7 (65.6 to 73.6)30.3 (26.4 to 34.5)
15C87.9 (85.1 to 90.3)76.2 (72.7 to 79.4)
16F63.2 (59.3 to 67.1)20.3 (17.2 to 23.7)
23A70.6 (66.3 to 74.6)34.7 (30.2 to 39.5)
23B86.6 (83.7 to 89.1)44.1 (40.2 to 48.1)
24F50.5 (46.2 to 54.7)14.6 (11.6 to 18.0)
3174.4 (70.8 to 77.7)18.3 (15.4 to 21.4)
35B63.8 (60.0 to 67.5)5.2 (3.6 to 7.1)
SecondaryPercentage of Participants With ≥4-Fold Rise From Baseline in Serotype-Specific IgG GMCs for All Serotypes in V116

The percentage of participants with ≥4-fold rise from baseline in serotype-specific IgG GMCs for all serotypes in V116 was determined using PnECL. The within-group CIs were calculated based on the Clopper-Pearson method.

Time frame:
Baseline (Day 1) and Day 30 postvaccination
Reported as:
Number · Percentage of Participants
Percentage of Participants With ≥4-Fold Rise From Baseline in Serotype-Specific IgG GMCs for All Serotypes in V116
Percentage of ParticipantsBase Study: V116Base Study: PPSV23
359.8 (56.1 to 63.4)54.7 (51.0 to 58.4)
7F84.8 (81.9 to 87.4)79.7 (76.6 to 82.6)
884.4 (81.5 to 87.0)86.5 (83.7 to 88.9)
9N85.5 (82.7 to 88.0)83.2 (80.3 to 85.9)
10A88.9 (86.3 to 91.1)81.1 (78.1 to 83.9)
11A76.8 (73.5 to 79.8)56.6 (52.8 to 60.2)
12F86.5 (83.7 to 88.9)73.7 (70.4 to 76.9)
17F91.0 (88.6 to 93.0)79.6 (76.5 to 82.5)
19A63.9 (60.3 to 67.5)58.5 (54.8 to 62.2)
20A85.5 (82.7 to 88.0)73.3 (69.9 to 76.5)
22F85.4 (82.5 to 87.9)77.5 (74.3 to 80.5)
33F83.0 (80.0 to 85.7)83.5 (80.6 to 86.2)
6A81.4 (78.3 to 84.2)47.3 (43.6 to 51.1)
15A91.3 (88.9 to 93.2)34.2 (30.7 to 37.8)
15C90.7 (88.3 to 92.7)72.1 (68.6 to 75.3)
16F83.8 (80.9 to 86.4)11.3 (9.1 to 13.9)
23A85.9 (83.1 to 88.4)29.9 (26.6 to 33.4)
23B78.9 (75.7 to 81.8)33.1 (29.7 to 36.7)
24F88.2 (85.5 to 90.4)1.7 (0.9 to 2.9)
3182.0 (78.9 to 84.7)11.6 (9.3 to 14.2)
35B85.1 (82.2 to 87.6)2.1 (1.2 to 3.4)

Adverse events

Collected over Up to 24 months postvaccination.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Base Study: V1160/741 (0%)22/739 (3%)399/739 (54%)
Base Study: PPSV230/743 (0%)18/741 (2.4%)364/741 (49.1%)
Immunogenicity Substudy: V1160/349 (0%)0/349 (0%)0/349 (0%)
Immunogenicity Substudy: PPSV230/348 (0%)0/348 (0%)0/348 (0%)
PBMC Sub-study: V1160/41 (0%)0/41 (0%)0/41 (0%)
PBMC Sub-study: PPSV230/39 (0%)0/39 (0%)0/39 (0%)
Most frequent serious events
Showing 10 of 43
Most frequent serious events
EventBase Study: V116Base Study: PPSV23Immunogenicity Substudy: V116Immunogenicity Substudy: PPSV23PBMC Sub-study: V116PBMC Sub-study: PPSV23
ExtrasystolesCardiac disorders1/7390/7410/3490/3480/410/39
Mitral valve incompetenceCardiac disorders1/7390/7410/3490/3480/410/39
Sinus bradycardiaCardiac disorders1/7390/7410/3490/3480/410/39
Thyroid massEndocrine disorders1/7391/7410/3490/3480/410/39
Abdominal wall haematomaGastrointestinal disorders1/7390/7410/3490/3480/410/39
Chest painGeneral disorders1/7391/7410/3490/3480/410/39
CholecystitisHepatobiliary disorders1/7390/7410/3490/3480/410/39
Abdominal infectionInfections and infestations1/7390/7410/3490/3480/410/39
InfluenzaInfections and infestations1/7390/7410/3490/3480/410/39
Osteomyelitis chronicInfections and infestations1/7390/7410/3490/3480/410/39
Most frequent other events
Most frequent other events
EventBase Study: V116Base Study: PPSV23Immunogenicity Substudy: V116Immunogenicity Substudy: PPSV23PBMC Sub-study: V116PBMC Sub-study: PPSV23
Injection site painGeneral disorders301/739261/7410/3490/3480/410/39
HeadacheNervous system disorders124/739105/7410/3490/3480/410/39
FatigueGeneral disorders122/739118/7410/3490/3480/410/39
Injection site erythemaGeneral disorders58/73947/7410/3490/3480/410/39
Injection site swellingGeneral disorders48/73932/7410/3490/3480/410/39
MyalgiaMusculoskeletal and connective tissue disorders43/73946/7410/3490/3480/410/39

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Base Study: V116Base Study: PPSV23Total
Mean63.9 ± 8.463.7 ± 8.363.8 ± 8.3
Sex: Female, Male
Sex: Female, Male(Participants)Base Study: V116Base Study: PPSV23Total
Female332333665
Male409410819
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Base Study: V116Base Study: PPSV23Total
Hispanic or Latino151162313
Not Hispanic or Latino5795711150
Unknown or Not Reported111021
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Base Study: V116Base Study: PPSV23Total
American Indian or Alaska Native459
Asian151140291
Native Hawaiian or Other Pacific Islander9312
Black or African American224
White455469924
More than one race119124243
Unknown or Not Reported101
08

Study locations

55 sites
  • Fundacion Estudios Clinicos ( Site 0200)
    Rosario, Santa Fe Province S2000DEJ, Argentina
  • Paratus Clinical Research Western Sydney ( Site 1500)
    Blacktown, New South Wales 2148, Australia
  • Northern Beaches Clinical Research ( Site 1502)
    Brookvale, New South Wales 2100, Australia
  • Paratus Clinical Research Brisbane ( Site 1501)
    Albion, Queensland 4010, Australia
  • IPS Centro Científico Asistencial S.A.S ( Site 0407)
    Barranquilla, Atlántico 80020, Colombia
  • Fundacion Valle del Lili- CIC ( Site 0415)
    Cali, Valle del Cauca Department 760032, Colombia
  • klinikum rechts der isar der technischen universität münchen ( Site 0904)
    München, Bavaria 81675, Germany
  • InfektioResearch ( Site 0903)
    Frankfurt am Main, Hesse 60596, Germany
  • Universitaetsklinikum Koeln ( Site 0900)
    Cologne, North Rhine-Westphalia 50937, Germany
  • Medizentrum Essen Borbeck ( Site 0902)
    Essen, North Rhine-Westphalia 45355, Germany
  • Universitaetsklinikum Hamburg-Eppendorf-Infektiologie ( Site 0901)
    Hamburg, 20246, Germany
  • Rambam Health Care Campus ( Site 1002)
    Haifa, 3109601, Israel
  • Hadassah Medical Center-Clinical Reaserch Unit ( Site 1004)
    Jerusalem, 9112001, Israel
  • Meir Medical Center-Infectious unit ( Site 1003)
    Kfar Saba, 4428164, Israel
  • Sheba Medical Center ( Site 1000)
    Ramat Gan, 5265601, Israel
  • Clalit Health Services - Sakhnin Community Clinic-Research Unit ( Site 1001)
    Sakhnin, 3081000, Israel
  • P3 Research - Palmerston North ( Site 1602)
    Palmerston North, Manawatu-Wanganui 4414, New Zealand
  • P3 Research - Lower Hutt ( Site 1601)
    Lower Hutt, Wellington Region 5010, New Zealand
  • Optimal Clinical Trials ( Site 1600)
    Auckland, 1010, New Zealand
  • Wonju Severance Christian Hospital ( Site 1808)
    Wŏnju, Kang-won-do 26426, South Korea
  • Chonnam National University Hospital-Infectious Diseases ( Site 1811)
    Gwangju, Kwangju-Kwangyokshi 61469, South Korea
  • Korea University Ansan Hospital ( Site 1801)
    Ansan-si, Kyonggi-do 15355, South Korea
  • Soon Chun Hyang University Bucheon Hospital ( Site 1812)
    Bucheon-si, Kyonggi-do 14584, South Korea
  • Hallym University Dongtan Sacred Heart Hospital ( Site 1813)
    Hwaseong-si, Kyonggi-do 18450, South Korea
  • The Catholic University Of Korea St. Vincent's Hospital-Internal Medicine ( Site 1803)
    Suwon, Kyonggi-do 16247, South Korea
  • Dong-A University Hospital ( Site 1810)
    Busan, Pusan-Kwangyokshi 49201, South Korea
  • Kyungpook National University Chilgok Hospital-Division of Infectious Diseases ( Site 1804)
    Deagu, Taegu-Kwangyokshi 41404, South Korea
  • Chungnam national university hospital ( Site 1814)
    Junggu, Taejon-Kwangyokshi 35015, South Korea
  • The Catholic University of Korea, Eunpyeong St. Mary's Hospital ( Site 1802)
    Seoul, 03312, South Korea
  • Asan Medical Center ( Site 1809)
    Seoul, 05505, South Korea
  • The Catholic Univ. of Korea Seoul St. Mary's Hospital ( Site 1806)
    Seoul, 06591, South Korea
  • Hallym University Kangnam Sacred Heart Hospital ( Site 1807)
    Seoul, 07441, South Korea
  • Ewha Womans University Mokdong Hospital-Infectious Diseases ( Site 1805)
    Seoul, 07985, South Korea
  • Korea University Guro Hospital ( Site 1800)
    Seoul, 08308, South Korea
  • EBA CENTELLES ( Site 1100)
    Centelles, Catalonia 08500, Spain
  • Hospital Universitario Getafe ( Site 1111)
    Getafe, Madrid, Comunidad de 28905, Spain
  • Fundación Oftalmologica del Mediterraneo-Vaccine Research ( Site 1118)
    Valencia, Valenciana, Comunitat 46015, Spain
  • Centre d'Atenció Primària Vallcarca - Sant Gervasi ( Site 1101)
    Barcelona, 08023, Spain
  • EAP Sardenya ( Site 1102)
    Barcelona, 08025, Spain
  • Hospital La Princesa-Clinical Pharmacology ( Site 1115)
    Madrid, 28006, Spain
  • Kaohsiung Medical University Chung-Ho Memorial Hospital-Infectious diseases Division, Department of
    Kaohsiung City, 807, Taiwan
  • National Cheng Kung University Hospital ( Site 1901)
    Tainan, 704, Taiwan
  • National Taiwan University Hospital ( Site 1900)
    Taipei, 100, Taiwan
  • Chang Gung Medical Foundation-Linkou Branch ( Site 1902)
    Taoyuan, 333, Taiwan
  • Sancaktepe Şehit Prof.Dr. İlhan Varank Eğitim ve Arastirma Hastanesi ( Site 1305)
    Sancaktepe, Istanbul 34785, Turkey (Türkiye)
  • ANKARA UNIVERSITY IBNI SINA HOSPITAL ( Site 1304)
    Ankara, 06230, Turkey (Türkiye)
  • Hacettepe Universite Hastaneleri-İnfection ( Site 1300)
    Ankara, 06230, Turkey (Türkiye)
  • Gazi University Health Research and Application Center Gazi Hospital-Enfeksiyon Hastalıkları ( Site
    Ankara, 06560, Turkey (Türkiye)
  • Acibadem Universitesi Atakent Hastanesi-Infectious Disease ( Site 1301)
    Istanbul, 34303, Turkey (Türkiye)
  • Accellacare - Yorkshire-MeDiNova Yorkshire ( Site 1405)
    Shipley, Bradford BD18 3SA, United Kingdom
  • Barts Health NHS Trust-William Harvey Clinical Research Centre ( Site 1407)
    London, England EC1M 6BQ, United Kingdom
  • Royal Free Hospital-Ian Charleson Day Centre RESEARCH ( Site 1402)
    London, England NW32QG, United Kingdom
  • Layton Medical Centre ( Site 1400)
    Blackpool, Lancashire FY3 7EN, United Kingdom
  • Accellacare - Northamptonshire ( Site 1403)
    Corby, Northamptonshire NN18 9EZ, United Kingdom
  • Accellacare - Warwickshire ( Site 1404)
    Coventry, Warwickshire CV3 4FJ, United Kingdom
09

References and documents

Publications

  • Jotterand V, Jagannath V, Diaz AA, Velez JD, Letica A, Perez SN, Clark R, Caraco Y, Degen O, Park KH, Unal S, Wittke F, Hurtado K, Churchill C, Zhang Y, Fernsler D, Li J, Buchwald UK, Platt H. A Phase 3 Randomized Trial Investigating the Safety, Tolerability, and Immunogenicity of V116, an Adult-Specific Pneumococcal Vaccine, Compared with PPSV23, in Adults >/=50 Years of Age (STRIDE-10). Vaccines (Basel). 2025 Mar 22;13(4):341. doi: 10.3390/vaccines13040341. PubMed 40333240 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2022 to primary completion in Oct 2023, 11 months.

Results were first posted in Oct 2024, 1 year after primary completion.

Of 81 industry-sponsored phase 3 interventional studies under Pneumococcal Infections, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 23. This study's 11 months is close to that.

Counting every sponsor, half of 82 studies reached it within 13 months; a quarter within 9 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 4, 2022
First posted
Oct 6, 2022
StartActual
Nov 7, 2022
Primary completionActual
Oct 30, 2023
CompletionActual
Feb 7, 2025
Results first posted
Oct 31, 2024
Last update
Mar 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05569954
Responsible party
Sponsor
First posted
Oct 6, 2022
Start date
Nov 7, 2022
Primary completion
Oct 30, 2023
Completion
Feb 7, 2025
Results posted
Oct 31, 2024
Last update
Mar 2, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pneumococcal 21-Valent Conjugate Vaccine

Start the discussion